We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
Evolution Petroleum
EPM
$131M
| $216K | ﹤0.01% |
26,976
+1,147
| +4% | +$9.78K |
|
2627
Trupanion
TRUP
$1.07B
| $216K | ﹤0.01% |
15,167
+576
| +4% | +$8.79K |
|
|
CVLY
2628
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $216K | ﹤0.01% |
9,635
+441
| +5% | +$10.1K |
|
|
CEMP
2629
DELISTED
Cempra, Inc.
CEMP
| $216K | ﹤0.01% |
57,658
+3,471
| +6% | +$12K |
|
2630
Goldgroup Mining Inc.
GORO
$168M
| $215K | ﹤0.01% |
47,632
+1,942
| +4% | +$9.97K |
|
|
CCXI
2631
DELISTED
ChemoCentryx, Inc.
CCXI
| $214K | ﹤0.01% |
29,343
+868
| +3% | +$6.25K |
|
2632
Wave Life Sciences
WVE
$1.11B
| $212K | ﹤0.01% |
+7,702
| New | +$215K |
|
2633
Mitek Systems
MITK
$771M
| $211K | ﹤0.01% |
31,699
+1,382
| +5% | +$8.52K |
|
2634
Oppenheimer Holdings
OPY
$1.19B
| $211K | ﹤0.01% |
12,365
+461
| +4% | +$7.97K |
|
2635
Lineage Cell Therapeutics
LCTX
$277M
| $210K | ﹤0.01% |
69,718
+4,833
| +7% | +$13.7K |
|
|
INFI
2636
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $210K | ﹤0.01% |
65,077
+17,452
| +37% | +$42.9K |
|
|
PFBI
2637
DELISTED
Premier Financial Bancorp
PFBI
| $210K | ﹤0.01% |
+12,484
| New | +$191K |
|
|
COUP
2638
DELISTED
Coupa Software Incorporated
COUP
| $209K | ﹤0.01% |
+8,248
| New | +$211K |
|
|
IHC
2639
DELISTED
Independence Holding Company
IHC
| $209K | ﹤0.01% |
11,234
+333
| +3% | +$6.29K |
|
2640
Ocular Therapeutix
OCUL
$1.85B
| $208K | ﹤0.01% |
22,428
+3,493
| +18% | +$29.1K |
|
|
CRCM
2641
DELISTED
CARE.COM, INC.
CRCM
| $208K | ﹤0.01% |
16,666
-120
| -0.7% | -$1.19K |
|
2642
Duluth Holdings
DLTH
$154M
| $206K | ﹤0.01% |
9,668
+371
| +4% | +$8.26K |
|
2643
Trade Desk
TTD
$8.59B
| $206K | ﹤0.01% |
+55,280
| New | +$189K |
|
|
OMED
2644
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $206K | ﹤0.01% |
22,417
+2,179
| +11% | +$19.1K |
|
2645
INNOVATE Corp
VATE
$111M
| $205K | ﹤0.01% |
3,310
+216
| +7% | +$13.4K |
|
2646
Clearfield
CLFD
$420M
| $204K | ﹤0.01% |
12,385
+439
| +4% | +$7.76K |
|
2647
Option Care Health
OPCH
$3.36B
| $203K | ﹤0.01% |
29,784
+400
| +1% | +$2.65K |
|
|
RPT
2648
Rithm Property Trust
RPT
$97.2M
| $203K | ﹤0.01% |
2,677
+120
| +5% | +$9.16K |
|
2649
Anavex Life Sciences
AVXL
$250M
| $202K | ﹤0.01% |
35,137
+1,429
| +4% | +$7.38K |
|
|
MOBL
2650
DELISTED
MobileIron, Inc.
MOBL
| $201K | ﹤0.01% |
46,235
+2,176
| +5% | +$9.63K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.